212 related articles for article (PubMed ID: 24530273)
1. A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder.
Kennedy SH; Avedisova A; Giménez-Montesinos N; Belaïdi C; de Bodinat C;
Eur Neuropsychopharmacol; 2014 Apr; 24(4):553-63. PubMed ID: 24530273
[TBL] [Abstract][Full Text] [Related]
2. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
Hale A; Corral RM; Mencacci C; Ruiz JS; Severo CA; Gentil V
Int Clin Psychopharmacol; 2010 Nov; 25(6):305-14. PubMed ID: 20856123
[TBL] [Abstract][Full Text] [Related]
3. Major depressive disorder, anhedonia and agomelatine: an open-label study.
Di Giannantonio M; Di Iorio G; Guglielmo R; De Berardis D; Conti CM; Acciavatti T; Cornelio M; Martinotti G
J Biol Regul Homeost Agents; 2011; 25(1):109-14. PubMed ID: 21382280
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
Olié JP; Kasper S
Int J Neuropsychopharmacol; 2007 Oct; 10(5):661-73. PubMed ID: 17477888
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.
Stein DJ; Ahokas AA; de Bodinat C
J Clin Psychopharmacol; 2008 Oct; 28(5):561-6. PubMed ID: 18794654
[TBL] [Abstract][Full Text] [Related]
6. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
Goodwin GM; Emsley R; Rembry S; Rouillon F;
J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920
[TBL] [Abstract][Full Text] [Related]
7. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.
Lôo H; Hale A; D'haenen H
Int Clin Psychopharmacol; 2002 Sep; 17(5):239-47. PubMed ID: 12177586
[TBL] [Abstract][Full Text] [Related]
8. Agomelatine: efficacy at each phase of antidepressant treatment.
Kennedy SH
CNS Drugs; 2009; 23 Suppl 2():41-7. PubMed ID: 19708725
[TBL] [Abstract][Full Text] [Related]
9. Agomelatine, a melatonin agonist with antidepressant properties.
Dubovsky SL; Warren C
Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108
[TBL] [Abstract][Full Text] [Related]
10. Treating each and every depressed patient.
Kennedy SH
J Psychopharmacol; 2008 Sep; 22(7 Suppl):19-23. PubMed ID: 18753279
[TBL] [Abstract][Full Text] [Related]
11. [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders].
Lôo H; Daléry J; Macher JP; Payen A
Encephale; 2002; 28(4):356-62. PubMed ID: 12232545
[TBL] [Abstract][Full Text] [Related]
12. [A comparative evaluation of the efficacy of valdoxan (agomelatine) in recurrent depression and bipolar affective disorder].
Tiuvina NA; Smirnova VN
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(11 Pt 2):53-60. PubMed ID: 23257757
[TBL] [Abstract][Full Text] [Related]
13. Agomelatine in the treatment of seasonal affective disorder.
Pjrek E; Winkler D; Konstantinidis A; Willeit M; Praschak-Rieder N; Kasper S
Psychopharmacology (Berl); 2007 Mar; 190(4):575-9. PubMed ID: 17171557
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial.
Zajecka J; Schatzberg A; Stahl S; Shah A; Caputo A; Post A
J Clin Psychopharmacol; 2010 Apr; 30(2):135-44. PubMed ID: 20520286
[TBL] [Abstract][Full Text] [Related]
15. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
Stahl SM; Fava M; Trivedi MH; Caputo A; Shah A; Post A
J Clin Psychiatry; 2010 May; 71(5):616-26. PubMed ID: 20361916
[TBL] [Abstract][Full Text] [Related]
16. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
Kasper S; Hamon M
World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
[TBL] [Abstract][Full Text] [Related]
17. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
San L; Arranz B
Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
[TBL] [Abstract][Full Text] [Related]
18. The use of antidepressants in clinical practice: focus on agomelatine.
McAllister-Williams RH; Baldwin DS; Haddad PM; Bazire S
Hum Psychopharmacol; 2010 Mar; 25(2):95-102. PubMed ID: 20196187
[TBL] [Abstract][Full Text] [Related]
19. Agomelatine, an innovative pharmacological response to unmet needs.
Le Strat Y; Gorwood P
J Psychopharmacol; 2008 Sep; 22(7 Suppl):4-8. PubMed ID: 18753276
[TBL] [Abstract][Full Text] [Related]
20. Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.
Bourin M; Prica C
Curr Pharm Des; 2009; 15(14):1675-82. PubMed ID: 19442180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
